NASDAQ
04.03.26 | 21:58
5,675 US-Dollar
-1,48 % -0,085
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.02. | Foghorn Therapeutics appoints Ryan Maynard as CFO | 1 | Seeking Alpha | ||
| 23.02. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer | 95 | GlobeNewswire (Europe) | WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen | |
| 23.02. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.02. | Jefferies stuft Foghorn Therapeutics mit "Buy" ein und sieht erhebliches Potenzial | 2 | Investing.com Deutsch | ||
| 17.02. | Jefferies initiates Foghorn Therapeutics stock with buy rating | 13 | Investing.com | ||
| 13.01. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium | 153 | GlobeNewswire (Europe) | WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen | |
| FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.01. | Foghorn Therapeutics stock reaffirmed as Buy by BTIG, named top pick for 1H26 | 3 | Investing.com | ||
| 12.01. | Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 target | 2 | Investing.com | ||
| 12.01. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.01. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 | 478 | GlobeNewswire (Europe) | Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026 Phase... ► Artikel lesen | |
| 18.12.25 | BTIG stuft Foghorn Therapeutics mit "Buy" ein - Potenzial in der Krebs-Pipeline | 2 | Investing.com Deutsch | ||
| 18.12.25 | BTIG initiates Foghorn Therapeutics stock with Buy rating on cancer pipeline | 1 | Investing.com | ||
| 04.12.25 | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target | 1 | Investing.com | ||
| 07.11.25 | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11.25 | Foghorn Therapeutics GAAP EPS of -$0.25 beats by $0.08, revenue of $8.15M beats by $1.95M | 6 | Seeking Alpha | ||
| 05.11.25 | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.10.25 | Foghorn advances protein degrader programs for cancer treatment | 1 | Investing.com | ||
| 30.10.25 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs | 243 | GlobeNewswire (Europe) | - Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors... ► Artikel lesen | |
| 30.10.25 | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 15,120 | +5,04 % | Erasca, Inc. (ERAS): A Bull Case Theory | ||
| QIAGEN | 40,875 | +0,43 % | Shortseller-Positionen aktuell: freenet, Gerresheimer, Hypoport, Qiagen, Renk, Suss MicroTec, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,230 | -5,67 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | - Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen... ► Artikel lesen | |
| BIONTECH | 89,10 | -0,11 % | BioNTech Aktie: Die Wende naht! Golden Cross! | © Foto: 2026 BioNTech SE. Alle Recht vorbehalten.Fast wie in der Serie "Game of Thrones", wo der Winter naht, könnte bei BioNTech die Wende nahen. Nach dem Kursrausch in der Corona-Ära folgte der brutale... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 12,865 | 0,00 % | Day One BioPharmaceuticals gains amid takeover speculation | ||
| ADMA BIOLOGICS | 16,545 | -0,21 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| MODERNA | 49,585 | -0,17 % | Moderna: Kombi-Impfung für Grippe und Covid erhält Zulassung | Gute Nachrichten für Moderna: Die EU-Arzneimittelbehörde EMA hat grünes Licht gegeben für den ersten Kombi-Impfstoff gegen Corona und Grippe. Der Wirkstoff solle für Menschen ab 50 Jahren zugelassen... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 86,15 | -4,39 % | Kymera auf TD Cowen Konferenz: Strategische Einblicke in Medikamenten-Pipeline und Partnerschaften | ||
| EVOTEC | 5,652 | +6,56 % | Evotec Aktie vor dem Durchbruch? Diesmal ist etwas anders... | Die Evotec Aktie hat zuletzt ein wichtiges Muster bestätigt: Wiederholt scheiterte die Biotech-Aktie aus Hamburg mit Breakversuchen an der 200-Tage-Linie. Nach mehr oder weniger starken Ausbrüchen hierüber... ► Artikel lesen | |
| ARCELLX | 114,26 | +0,18 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| TYRA BIOSCIENCES | 35,240 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 3,820 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated,... ► Artikel lesen | |
| CG ONCOLOGY | 61,50 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 27,410 | +19,17 % | Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF")... ► Artikel lesen | |
| UPSTREAM BIO | 7,800 | +1,56 % | Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting | - Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p in new analysis with adjustment for concomitant rescue therapy use - - Secondary endpoints also provided strong... ► Artikel lesen |
FOGHORN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 5,675 Euro und damit -1,48 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FOGHORN THERAPEUTICS INC finden Sie auf Wallstreet Online.